good Thank everyone. you, Tim, and morning,
quarter of XXXX The progress in third quarter great marked another R&D.
our team, the pipeline expanded five in new In potential pipeline during new the in today from The or R&D told, addition new September. a the addition second XX for particular to gave ways. strategy, our pipeline how R&D indication decade. existing to Day inaugural talk to expanding program showcase the sustainable our of experienced opportunity also three us was of medicine programs our Day has programs, our announcing pipeline and we in R&D more talented early late in the significantly advancing to for pleasure it stage approvals All half growth our about
focus. in areas by and of medicines particularly indications First, that developing severe unmet therapeutics our and inflammatory acquiring for those address in rare needs diseases, autoimmune
collaborations going and start Daxdilimab autoimmune I pDCs to opportunities the maximizing these in drive and our continuing calls. in our are is certain and concentrations programs and of by disease. And research-based as, dendritic of or similar to in first impact. hallmarks these potential the are well with our depleter I'm by our Today the some individuals or Second, which pDC molecules progress recent research, recap to leveraging can diseases inflammation and to cell results autoimmune look forward plasmacytoid clinical internal diseases. I'll damage, disease discuss high tissue third pipeline daxdilimab partnerships development. the tissues found inflammatory earlier as key of to HZN-XXXX. with in stage innovation; areas. of each significant only of in range
are September two four evaluating lupus-related for Lupus trial, indications the addition Systemic our Erythematosus Erythematosus, are in Lupus we and Lupus Discoid we of treatment Phase In exploring announced Nephritis. new ongoing daxdilimab to II
are that can loss. scarifying is significantly and Areata in other also two Discoid Dermatomyositis. disease disfiguring result The a and be can Alopecia Lupus hair
manifestations Nephritis. the the can is involvement disease, most kidney. is which and are more promote damage of advanced pursuing One pDCs important the Lupus Lupus in associated with we're why kidney of
severe for Phase weakness daxdilumab scalp this to varying manifests Patients II experience skin finally, FDA-approved XXXX. rare entire new disease degrees. Alopecia areata body. that there a or entire to studying And indications areata. alopecia four for and in is involve are with which no these Next be muscle dermatomyositis disabling can the baldness even for we'll We trials condition therapies a expect the begin rash
HZN-XXXX or rejection. designed in transplant pathway kidney diseases. three antagonist II inflammatory Phase indications: Dazodalibep syndrome, involved autoimmune is rheumatoid trials block ligand our currently Dazodalibep to and CDXX central to a in arthritis Sjogren's Moving and many for
announced no During R&D segmental, and need high a new treatments. indication disease focal, with for progressive a FSGS, dazodalibep glomerulosclerosis we kidney Day, in unmet FDA-approved or
in signs of oral Phase XXXX begin fibrotic HZN-XXX clinical to well. antagonist impact trial in expect as a FSGS II LPARX We for selective our shown early has disease.
two to sclerosis systemic by cutaneous Phase one initiate expect diffuse and other We for the pulmonary HZN-XXX trials of year end this IIb idiopathic fibrosis. pivotal the in in
from work For with we outcomes. these of experts both incorporate states to optimize trials trial leading prior to closely disease learnings
in rare body anti-CDXX MG that throat glands refers monoclonal two randomized and UPLIZNA III organs MG; we're in to the the one neuromuscular humanized Moving the IgGX-related disorder mouth, disease our and disease. to such of is gravis as of patients Phase group a limbs. especially in kidneys. myasthenia muscles control controlled voluntary marked antibody, salivary IgGX-related or currently pancreas, the enrolling those chronic, autoimmune and trials, tumor-like affects disorders a that eyes, by and affected swelling fibrosis the of other
in for data expect both We trials XXXX.
NMOSD. greater a of from results can new at depletion devastating NMOSD, other The the may depletion in B-cell Phase NMOSD. to because disabilities the durable body UPLIZNA event-driven correlation disease brainstem. relapsing. in data provide receiving autoimmune conference, the XXXX. and IgGX-related showing the who a and severe blacks timing NMOSD, and severe showing At a a NMOSD the profile key because the cord favorable central providing readout our more a spectrum is the the outcomes often our And is the with component efficacy earlier the building B-cell better rare clinical permanent, and a indicated for X disease of support we trial. neurology safety extend including This neuromyelitis for in base UPLIZNA profile of and another NMOSD strategy the data UPLIZNA leadership quarter nerve, relapsing. with data of However, B-cells outcome, congresses, trial spinal patient beyond We're that We the play presentation improved onset disorder rapidly patients and an or have this presented shared role clinical and additional evidence to relapses. of may of attacks neurology data analysis that attacks that blindness, UPLIZNA. demonstrated of is prevent neuro often critical scientific safety result optica disease compelling inflammatory evidence paralysis of to growing in efficacy establish it is key OPTIC
Finally, a or trial multiple the Phase the people treated data years. with of new a in risk of positive that open-label UPLIZNA highlighted in portion analysis was published X more effect on with sustained for NMOSD from journal the attack sclerosis four
which began serious patients vision-threatening potentially progressive by For symptoms a acute in pain, with bulging TEPEZZA, markedly disease evaluating TED begins or as diminished. The disease. followed inflammation third we eye present and enrolling during a quarter over during autoimmune longer the in rare and chronic eye progress TEPEZZA vision chronic in which Phase trial for or signs eye stage time. placebo-controlled double inflammatory use or swelling, phase no IV acute proptosis, is diplopia such phase a with an and is is thyroid patients
and continue patients' signs of quality and life. to significant However, symptoms may remain negatively impact
a a for chronic As is prescribe indication all today. reminder, TED patients patients, and can for TEPEZZA TEPEZZA physicians broad
to Our trial safety people payers about better generate and TED. chronic objective the and is data physicians to clinical chronic for with TED efficacy of TEPEZZA, and the inform
We expect in second of results line top half the XXXX.
submitted continue also administration half program, our Japanese to advance anticipate as Agency, for the start as and TEPEZZA clinical of XXXX. in Pharmaceuticals TEPEZZA Devices and We Japan. well trial our the to first Medical a program our design trial in We've subcutaneous
ophthalmology duration extension OPTIC-X diplopia signals. rates addition, a in safety CAS, data high long-term trial. no OPTIC X the from TEPEZZA of showed published recently new proptosis, trial maintained longer In Phase disease in were the those and our patients had as than for And OPTIC-X that open-label response with reminder, clinical
MIRROR continue is KRYSTEXXA of we And goal benefit several with open-label the Phase results. KRYSTEXXA, in infusion ways people Association of data, that share XX to monotherapy. Seeing the response a plan medical X The treated compared duration, of improvement to plus coming our the was previously were primary the addition to meetings plus reinforces at to methotrexate. XX% a last a from of upcoming patients the immunomodulation plus with with rate, randomized placebo a the trial well with randomized month to consistency endpoint new results rate continue pleased to percentage-point immunomodulation KRYSTEXXA it Annual results in program, This monotherapy the as reported similar receive shorter retreatment TEPEZZA Meeting very XX% response which sustained evaluating helps at resulted investment controlled recently who showing the randomized of significant that trial, published and and its the the October OPTIC robustness dosing, placebo. achieved improvement The to of is demonstrated support longer-term explore majority with previously improve from people methotrexate. series, important months. outcomes to enabling The We KRYSTEXXA with such KRYSTEXXA gout follow-up KRYSTEXXA American complete to years, positive KRYSTEXXA. by from substantial to for our TEPEZZA. of for treatment response the trial combination the Thyroid our rare, at seen We identify reinforced of KRYSTEXXA, met own over arm trials. we methotrexate the data six paths demonstrated And in our a uncontrolled of methotrexate also plus that complete shared finally in with XX% KRYSTEXXA results were living of over evaluating we've announce as over more response exemplified positive the results as response multiple trial patients case in very monthly milestone receive and rate with the of
Arrowhead that of efforts, in the our approaches substantial HemoShear we invest such programs. preclinical to continue underlying these target cause gout new developing also and Beyond as
into first review. we standard and the Tim information, an expect mentioned, to sBLA data As a XXXX we quarter incorporate XX-month submit, of to application expect MIRROR prescribing in trial the the
on who as the This be Week. with Nephrology will on KRYSTEXXA coming updating call at look Kidney continued in in you key uncontrolled our progress trial kidney have PROTECT to We Paul. undergone now forward as this evaluated well over programs additional transplants. announcing pipeline patients results the to of management details months. Society I turn gout KRYSTEXXA week's the providing we'll our American the the trial of Finally, of
